Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The GM1 Gangliosidosis Market Expected to Grow Between 2025 And 2029?

In recent times, we have seen a speedy expansion in the gm1 gangliosidosis market. The market size is projected to increase from $0.51 billion in 2024 to $0.57 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 11.1%. The substantial growth over the historical period is due to an increased number of gm1 gangliosidosis patients, expanding attention towards gm1 gangliosidosis space, growing awareness of rare diseases, increasing popularity of patient-focused research, and an escalating emphasis on early intervention.

In the next few years, the market for gm1 gangliosidosis is projected to experience a swift expansion, escalating to$0.87 billion in 2029″ with an 11.0% compound annual growth rate (CAGR). This expected growth during forecasted period is likely due to the increase in gm1 gangliosidosis incidences, the surge in lysosomal storage disorder, heightened frequency of clinical trials, rising emphasis on gene therapy and editing, the growing trend of personalized and precision medicine, and an increased uptake of genetic screening programs. Key trends during this forecasted period include improvements in gene-editing technologies, the melding of technology and healthcare, progress in diagnostic methods, advanced formulations, and progress in genetic therapies.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21194&type=smp

What External and Internal Drivers Are Contributing to the Growth of theGM1 Gangliosidosis Market?

The GM1 gangliosidosis market’s expansion is projected to be propelled by the growing implementation of gene therapy. Gene therapy is a medical approach that entails modifying or replacing genes within an individual’s cells to treat or forestall disease. The rise in the use of gene therapy is facilitated by developments in genetic research, enhanced results for previously incurable conditions, and increased regulatory endorsement for innovative treatments. Gene therapy for GM1 gangliosidosis entails providing a functioning copy of the faulty gene (GLB1) to the patient’s cells to revive β-galactosidase enzyme activity and diminish toxic substrate accumulation. For example, in April 2024, as per the American Society of Gene & Cell Therapy, a non-profit medical and scientific organization based in the US, the number of phase III gene therapy clinical trials escalated by 10% in the fourth quarter, recording the first quarterly rise since the third quarter of 2022. Hence, the escalating usage of gene therapy is fostering the growth of the GM1 gangliosidosis market.

What Segment Types Define the GM1 Gangliosidosis Market Structure?

The gm1 gangliosidosismarket covered in this report is segmented –

1) By Disease Type: Type 1 GM1 Gangliosidosis; Type 2 GMT Gangliosidosis; Type 3 GMT Gangliosidosis

2) By Treatment: Anticonvulsants; Bone Marrow Transplantation; Cord-Blood Hematopoietic Stem-Cell Transplantation; Enzyme Replacement; Gene Therapy

3) By End-User: Research Institutes; Hospitals; Other End-Users

Subsegments:

1) By Type 1 GM1 Gangliosidosis: Classic Infantile Onset; Atypical Infantile Onset

2) By Type 2 GM1 Gangliosidosis: Classic Juvenile Onset; Atypical Juvenile Onset

3) By Type 3 GM1 Gangliosidosis: Classic Adult Onset; Atypical Adult Onset

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21194&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the GM1 Gangliosidosis Market?

North America was the largest region in the GM1 gangliosidosis market in 2024. The regions covered in the GM1 gangliosidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the GM1 Gangliosidosis Market?

Leading businesses in the GM1 gangliosidosis market are leveraging strategic collaborations to maintain their market status. These partnerships are essential in furthering the progress of gene therapy by pooling skills, assets, and technologies for quicker research, clinical studies, and product launch. For example, GEMMA Biotherapeutics Inc., a biotech firm based in the U.S., teamed up with Brazil’s Oswaldo Cruz Foundation (Fiocruz), a health research entity, in October 2024 to develop gene therapies for uncommon ailments, such as GM1 gangliosidosis. The arrangement includes up to $100 million in funding from Fiocruz dedicated to clinical investigation and production, intending to make these sophisticated therapies available via Brazil’s public healthcare setup. This partnership stresses the transfer of technology and aims to broaden access to treatments formerly restricted to higher-earning segments of the population.

View the full report here:

https://www.thebusinessresearchcompany.com/report/gm1-gangliosidosis-global-market-report

What Is the Definition of the GM1 Gangliosidosis Market?

GM1 gangliosidosis is a rare, inherited neurodegenerative disorder caused by a deficiency of the β-galactosidase (GLB1) enzyme, leading to toxic accumulation of GM1 gangliosides in the brain and other tissues. It results in progressive neurological decline, developmental delays, muscle weakness, and organ enlargement.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21194

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model